Cargando…
Acquired Hemophilia A Successfully Treated with Rituximab
Acquired hemophilia A (AHA) is a rare bleeding disorder due to the development of specific autoantibodies against factor VIII. The anti-CD20 monoclonal antibody Rituximab has been proven to be effective in obtaining a long-term suppression of inhibitors of AHA, besides other immunosuppressive standa...
Autores principales: | D’Arena, Giovanni, Grandone, Elvira, Di Minno, Matteo Nicola Dario, Musto, Pellegrino, Di Minno, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344169/ https://www.ncbi.nlm.nih.gov/pubmed/25745551 http://dx.doi.org/10.4084/MJHID.2015.024 |
Ejemplares similares
-
Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies
por: D'Arena, Giovanni, et al.
Publicado: (2017) -
The Arrival of Gene Therapy for Patients with Hemophilia A
por: Castaman, Giancarlo, et al.
Publicado: (2022) -
Volanesorsen to treat severe hypertriglyceridaemia: A pooled analysis of randomized controlled trials
por: Calcaterra, Ilenia, et al.
Publicado: (2022) -
International recommendations on the diagnosis and treatment of acquired hemophilia A
por: Tiede, Andreas, et al.
Publicado: (2020) -
Fournier’s Gangrene Complicating Hematologic Malignancies: a Case Report and Review of Licterature
por: D’Arena, Giovanni, et al.
Publicado: (2013)